AC Immune (NASDAQ: ACIU) opened at $2.18 on Monday, marking a volatile start for the biopharmaceutical company amid fluctuations in the global stock exchange. The company’s performance… Read More
Futures Crash, Dow Down 600 As Recession Reality Sets In
In our preview of how to trade the Fed's 75bps rate hike, we said to expect a "kneejerk move higher (especially if… Read More
AC Immune SA (NASDAQ: ACIU) has announced that the second Phase 3 (CREAD 2) clinical trial of crenezumab, AC Immune’s anti-Abeta antibody candidate for treatment...
The post Healthcare… Read More
MasterTux / Pixabay
The healthcare stock market’s recent success is largely dependent on the fact that, as the global population increases and more people need access to healthcar… Read More